HUTCHMED (China) (HCM) Net Income towards Common Stockholders (2015 - 2021)
HUTCHMED (China)'s (HCM) quarterly Net Income towards Common Stockholders came in at $143.5 million in Q2 2021, up 1038.03% year-on-year from $12.6 million in Q2 2020, and up 448.88% on a QoQ basis from -$41.1 million in Q1 2021.
HUTCHMED (China) (HCM) Net Income towards Common Stockholders (2015 - 2021) Analysis & Trends
HUTCHMED (China) (HCM) has 6 years of Net Income towards Common Stockholders data on file, last reported at $143.5 million in Q2 2021.
- On a quarterly basis, Net Income towards Common Stockholders rose 1038.03% year-over-year to $143.5 million in Q2 2021; TTM through Dec 2022 was $143.5 million, a 40.18% increase from a year earlier, with the FY2025 full-year figure at $22.4 billion, changed 0.33% from the prior year.
- Net Income towards Common Stockholders for Q2 2021 stood at $143.5 million, up from -$41.1 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for HCM reached as high as $143.5 million in Q2 2021 and fell as low as -$121.8 million in Q3 2019.
- Historically, Net Income towards Common Stockholders has averaged $5.6 million across 4 years, with a median of $14.6 million in 2018.
- Across the five-year window, Net Income towards Common Stockholders tumbled 576.31% in 2019 and jumped 1038.03% in 2021, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at $16.5 million in 2018, then tumbled by 278.77% to -$29.6 million in 2019, then jumped by 142.67% to $12.6 million in 2020, then soared by 1038.03% to $143.5 million in 2021.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $143.5 million in Q2 2021, -$41.1 million in Q1 2021, and $12.6 million in Q2 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 57.00 Mn |
| 10 | HUTCHMED (China) | 9.45 Bn | 9.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 143.54 Mn |
| Mar 31, 2021 | -41.14 Mn |
| Jun 30, 2020 | 12.61 Mn |
| Mar 31, 2020 | -16.14 Mn |
| Dec 31, 2019 | -29.56 Mn |
| Sep 30, 2019 | -121.83 Mn |
| Jun 30, 2019 | 25.48 Mn |
| Mar 31, 2019 | 19.89 Mn |
| Dec 31, 2018 | 16.54 Mn |
| Sep 30, 2018 | 25.58 Mn |
| Jun 30, 2018 | 44.42 Mn |
| Mar 31, 2018 | -11.73 Mn |
| Jun 30, 2016 | 29.56 Mn |
| Jun 30, 2015 | 23.49 Mn |